Views & News

UK Equity Income Bulletin

| UK Equities
James Lowen
Clive Beagles
01 Nov 2017

Economic developments 

Economic momentum continued to be very strong across most of the developed world economies during the month, with many of the forward-looking indicators hitting multi-year highs. Examples included the German IFO Survey of business confidence hitting an all-time peak in October; the US Conference Board Consumer Confidence Index registering its highest level for 17 years; and the US ISM Manufacturing Index reaching a 13-year high and showing a particularly strong rate of acceleration in the last quarter. Furthermore, the rather more historic indicators of economic performance also showed consistently strong growth, with Q3 GDP growth in both the UK and the US exceeding expectations. It is this backdrop which is driving the somewhat co-ordinated withdrawal of stimulus by central banks across these regions. 

This withdrawal of stimulus is occurring in different ways and at different speeds, but the direction of travel is clear. The Fed looks to be clear in its resolve to further raise interest rates, even with the uncertainty of the new Governor’s appointment looming. In the UK, the reversal of the post-Brexit vote “temporary” monetary stimulus looks very likely to be confirmed at the November meeting, whilst in Europe the ECB has begun to taper its quantitative easing programme. On the latter, the debate about whether the decision to reduce the QE purchases to €30bn per month was more dovish than consensus or not rather misses the bigger picture, namely that the process of tapering has finally begun. 

In the UK, the most closely-watched release of the month (both by us and by Mr Carney) firmed slightly, with UK average weekly earnings rising 2.1% year-on-year. We strongly believe that with the reduced inward migration from Europe, labour shortages will intensify in the private sector. Coupled with the delicate political situation leading to less austerity and rising public sector awards, we expect to see growth in average earnings progressively move towards 3% over the next year. It is important to note that this measure tends to move glacially, not least because it is a rolling three-month average, so the publication of one extra month’s data has a limited immediate impact. However, the policy-makers at the Bank of England know that once the labour force rediscovers its collective bargaining power, the impact can be material and long-lasting, hence their focus upon this key indicator. At the same time, we would anticipate that the headline inflation data, which hit 3% this month, will progressively fall back from here as the base effects of the currency devaluation drop out. Consequently, the real wage squeeze will fade over the coming months.  

In Europe, whilst economic momentum has continued to build across the Continent, inevitably issues of political stability and collective unity still threaten to disrupt the recovery, not least in Catalonia. The election of the youngest ever leader in Austria is a reminder that extremist parties and anti-establishment platforms are likely to continue to grow in popularity across the region.  Concern in Brussels that similar movements will grow more powerful across Europe explains their desire to drive a relatively hard bargain with UK over its exit.     

The Brent oil price rose above US$60/bbl for the first time in two years and has now more than doubled from its low in January 2016. However, it still remains around 50% below the levels seen during 2014, and with the oil majors showing strong capital discipline, OPEC holding firm on its commitment to restrict output, and the weakening economics of shale operators in the US, we expect the commodity to continue to surprise many commentators. The deteriorating economics of the shale operators, with declining production and rising operating costs, is beginning to manifest itself in a slightly declining rig count in North America, despite the higher oil price. 

In Asia, China’s GDP growth continues to show resilience, with 6.8% printed in the third quarter. Demand for most industrial commodities remains firm, assisted by strong growth elsewhere in the world, with the 25% rise in the copper price so far in 2017 evidence of an improving supply/demand dynamic.    
           
Performance    

The market was strong during October, with the FTSE All-Share Total Return Index (12pm adjusted) posting an increase of 1.88%. The Fund continued to perform strongly compared to the benchmark, returning 2.67%. 

Year-to-date the Fund is up 14.68% versus the benchmark return of 10.37%. Looking at the peer group, the Fund is ranked first decile within the IA UK Equity Income sector over one year to 31 October 2017. On a longer-term basis, the Fund is ranked first decile over three years, 10 years and since launch (November 2004) and first quartile (second decile) over five years.

October is normally a ‘risk’ month for both the market and the Fund because there are usually a larger than normal number of profit warnings - any company that is not going to hit full-year forecasts, having seen its September results and October trends, has to announce to the market. And indeed there were a large number of warnings in October: Interserve, IWG, Pendragon, Dialight, Merlin, Carpetright, GKN and WPP all had sluggish statements. 

The Fund had two poor statements. Barclays (down 7% relative over the month) delivered a poor quarter, particularly in its investment bank, and whilst it produced useful timelines for its ROCE recovery and cost targets, the former rely on a big revenue recovery in the investment bank. Low & Bonar (down 13% relative over the month) also warned profits in one of its five divisions would be worse than expected. But the Fund also had a number of strong statements: BP, National Express, DS Smith (all three of which are in our top 10 active positions), Hollywood Bowl and Laird were all very positive. A large part of the Fund’s outperformance was linked to these trends. 

Elsewhere, both the wider oil and mining sectors performed well (up 2-5% relative), underpinned by rising commodity prices and a growing realisation of the strong cash flow characteristics in the mining sector. Keller and Northgate made ground following capital markets events in the latter part of September and early October respectively that both gave a strong message on future performance aspiration. Offsetting these positives was the generally sluggish performance of financials, ITV's continued underperformance (see below) and weakness in our retail names.

Another notable feature of the market in October was poor statements by a number of the ‘defensives’. GlaxoSmithKline, Reckitt Benckiser and Imperial Brands all had disappointing results, with many of their US-quoted peers also showing similar softness. The basic issue is a lack of revenue growth. This is caused by a multitude of issues, many of which we believe are structural (deflationary pricing, “infinite shelf”, lower barriers to entry, online competition, etc). The stumbling of the micro performance, coupled with high valuations (c. 20x P/E being the common ground) and the impact of rising bond yields, which we have discussed before, create a difficult combination. We remain very underweight in these areas. 

Portfolio activity

We added one new stock to the Fund in October in the form of international home improvement retail group Kingfisher, owner of brands such as B&Q and Screwfix in the UK and Brico Depot and Castorama in France. Its shares are trading around a 7-8 year relative low, on a P/E of c. 12.5x and currently yield nearly 4% while the company has c. £600m net cash on its balance sheet. 

The recently appointed management team has articulated a strategy that if executed would add £500m to annual profits by the year ending January 2021 (using 2016 as the base year when the group made c. £700m). This is a potential material step change in profitability about which the stock market is highly sceptical despite early evidence of traction. The £500m is to be generated by optimising operational efficiency (which should be relatively low risk), improving digital capability (which was needed) and creating a unified and unique offer that is sold across the group. The latter is the most material part of the total estimated gains (70%) but will be the most difficult to execute. On the current valuation, the share price is assuming no success with this new strategy, which creates a useful risk/reward dynamic.

The new strategy is not the only attraction of Kingfisher. Firstly, it also offers exposure to the recovering French economy (something that is hard to find via UK-listed stocks), with c. 40% of EBIT sourced from France via its ownership of Castorama and Brico Depot. Secondly, Screwfix (c. 20% of group EBIT) has one of the best organic growth records in the whole market, if considered separately. Thirdly, Kingfisher owns c. £3.5bn of freehold property. Fourthly and finally, it has a strong position in the vibrant Polish market. 

The weakest part of the group, in our view, is B&Q, which accounts for c. 25% of EBIT. However, this business will also benefit from the new strategy and investment in digital and could be boosted by a retrenchment by Bunnings, the Australian retailer that acquired Homebase a few years ago. Recent results from this business suggest the Bunnings UK axis is struggling. 

In other activity, we continued to add to recent new additions Hammerson and Central Asia Metals. We also continued to reduce our positions in both AstraZeneca and Laird into strength. We have outlined the rationale for these changes in recent monthly reports. In the former, we are now down to a c. 50bp overweight, with the stock being 3% of the Fund. AstraZeneca is our only holding in the pharmaceuticals sector; we do not own any GlaxoSmithKline, which, as noted above, had weak results; it also presented a confused picture on its dividend outlook. We continue to think Glaxo has a number of challenges, including its level of debt, potential liabilities from various put options, competitive challenges in a number of its large businesses (e.g. its HIV franchise) and that its P&L (and hence EPS and P/E-based valuations) does not include a number of material cash items (e.g. certain royalties). AstraZeneca has some of these traits, which is why we are comfortable reducing the weighting given how the share price has recovered, and in running a large underweight in the sector.

We also reduced DS Smith slightly, which has been a good performer recently, and Sainsbury, where near term trends, based on industry data, appear sluggish. We added to ITV, which continues to underperform despite evidence that TV advertising is recovering. We also topped up our Vodafone position, which has continued to perform poorly (down c. 10% relative the past year). 

Outlook

The path to policy normalisation has categorically begun in the US, the UK and Europe. The true distortive impact of effectively zero interest rates in the developed world on various asset classes will only become apparent in future years. However, without doubt it has pushed valuations of many assets and individual instruments to elevated levels that will be hard to justify if the cost of capital rises. There are also a number of geopolitical risks that also make for a more cautious tone – namely Korea, Trump’s progress (or lack of) on policy, Trump / Russia, the tensions in the Middle East, Brexit, etc.

Within the equity markets, we strongly believe that the overvaluation is most apparent in consumer staples and other perceived defensive sectors such as utilities and pharmaceuticals. It is pleasing that we are starting to see chinks in the armour in the operational performances of these businesses. Conversely, we believe that many of the areas that we are exposed to will respond well to a change of stock market leadership if monetary policy were to normalise, particularly financials. Elsewhere, valuations in both the oil and mining sectors continue to look attractive to us, whilst there are also selective opportunities in the UK domestic arena, too. 

The long-term performance of the Fund is heavily correlated to the Fund’s dividend growth and the resulting absolute level of the dividend. As we discussed two months ago, the dividend growth of the Fund remains robust – our current guidance is between 9-11% in 2017. We will provide a final update on the 2017 dividend growth in early December, with the risk remaining to the upside. The Fund yields c. 4.15% based on this 2017 dividend stream. This starting yield, strong dividend growth (which we expect to continue in 2018), the low valuations embedded across the portfolio, coupled with the shift in monetary policy, leave us cautiously optimistic in our outlook for the Fund. 
 

Economic developments 

Economic momentum continued to be very strong across most of the developed world economies during the month, with many of the forward-looking indicators hitting multi-year highs. Examples included the German IFO Survey of business confidence hitting an all-time peak in October; the US Conference Board Consumer Confidence Index registering its highest level for 17 years; and the US ISM Manufacturing Index reaching a 13-year high and showing a particularly strong rate of acceleration in the last quarter. Furthermore, the rather more historic indicators of economic performance also showed consistently strong growth, with Q3 GDP growth in both the UK and the US exceeding expectations. It is this backdrop which is driving the somewhat co-ordinated withdrawal of stimulus by central banks across these regions. 

This withdrawal of stimulus is occurring in different ways and at different speeds, but the direction of travel is clear. The Fed looks to be clear in its resolve to further raise interest rates, even with the uncertainty of the new Governor’s appointment looming. In the UK, the reversal of the post-Brexit vote “temporary” monetary stimulus looks very likely to be confirmed at the November meeting, whilst in Europe the ECB has begun to taper its quantitative easing programme. On the latter, the debate about whether the decision to reduce the QE purchases to €30bn per month was more dovish than consensus or not rather misses the bigger picture, namely that the process of tapering has finally begun. 

In the UK, the most closely-watched release of the month (both by us and by Mr Carney) firmed slightly, with UK average weekly earnings rising 2.1% year-on-year. We strongly believe that with the reduced inward migration from Europe, labour shortages will intensify in the private sector. Coupled with the delicate political situation leading to less austerity and rising public sector awards, we expect to see growth in average earnings progressively move towards 3% over the next year. It is important to note that this measure tends to move glacially, not least because it is a rolling three-month average, so the publication of one extra month’s data has a limited immediate impact. However, the policy-makers at the Bank of England know that once the labour force rediscovers its collective bargaining power, the impact can be material and long-lasting, hence their focus upon this key indicator. At the same time, we would anticipate that the headline inflation data, which hit 3% this month, will progressively fall back from here as the base effects of the currency devaluation drop out. Consequently, the real wage squeeze will fade over the coming months.  

In Europe, whilst economic momentum has continued to build across the Continent, inevitably issues of political stability and collective unity still threaten to disrupt the recovery, not least in Catalonia. The election of the youngest ever leader in Austria is a reminder that extremist parties and anti-establishment platforms are likely to continue to grow in popularity across the region.  Concern in Brussels that similar movements will grow more powerful across Europe explains their desire to drive a relatively hard bargain with UK over its exit.     

The Brent oil price rose above US$60/bbl for the first time in two years and has now more than doubled from its low in January 2016. However, it still remains around 50% below the levels seen during 2014, and with the oil majors showing strong capital discipline, OPEC holding firm on its commitment to restrict output, and the weakening economics of shale operators in the US, we expect the commodity to continue to surprise many commentators. The deteriorating economics of the shale operators, with declining production and rising operating costs, is beginning to manifest itself in a slightly declining rig count in North America, despite the higher oil price. 

In Asia, China’s GDP growth continues to show resilience, with 6.8% printed in the third quarter. Demand for most industrial commodities remains firm, assisted by strong growth elsewhere in the world, with the 25% rise in the copper price so far in 2017 evidence of an improving supply/demand dynamic.    
           
Performance    

The market was strong during October, with the FTSE All-Share Total Return Index (12pm adjusted) posting an increase of 1.88%. The Fund continued to perform strongly compared to the benchmark, returning 2.67%. 

Year-to-date the Fund is up 14.68% versus the benchmark return of 10.37%. Looking at the peer group, the Fund is ranked first decile within the IA UK Equity Income sector over one year to 31 October 2017. On a longer-term basis, the Fund is ranked first decile over three years, 10 years and since launch (November 2004) and first quartile (second decile) over five years.

October is normally a ‘risk’ month for both the market and the Fund because there are usually a larger than normal number of profit warnings - any company that is not going to hit full-year forecasts, having seen its September results and October trends, has to announce to the market. And indeed there were a large number of warnings in October: Interserve, IWG, Pendragon, Dialight, Merlin, Carpetright, GKN and WPP all had sluggish statements. 

The Fund had two poor statements. Barclays (down 7% relative over the month) delivered a poor quarter, particularly in its investment bank, and whilst it produced useful timelines for its ROCE recovery and cost targets, the former rely on a big revenue recovery in the investment bank. Low & Bonar (down 13% relative over the month) also warned profits in one of its five divisions would be worse than expected. But the Fund also had a number of strong statements: BP, National Express, DS Smith (all three of which are in our top 10 active positions), Hollywood Bowl and Laird were all very positive. A large part of the Fund’s outperformance was linked to these trends. 

Elsewhere, both the wider oil and mining sectors performed well (up 2-5% relative), underpinned by rising commodity prices and a growing realisation of the strong cash flow characteristics in the mining sector. Keller and Northgate made ground following capital markets events in the latter part of September and early October respectively that both gave a strong message on future performance aspiration. Offsetting these positives was the generally sluggish performance of financials, ITV's continued underperformance (see below) and weakness in our retail names.

Another notable feature of the market in October was poor statements by a number of the ‘defensives’. GlaxoSmithKline, Reckitt Benckiser and Imperial Brands all had disappointing results, with many of their US-quoted peers also showing similar softness. The basic issue is a lack of revenue growth. This is caused by a multitude of issues, many of which we believe are structural (deflationary pricing, “infinite shelf”, lower barriers to entry, online competition, etc). The stumbling of the micro performance, coupled with high valuations (c. 20x P/E being the common ground) and the impact of rising bond yields, which we have discussed before, create a difficult combination. We remain very underweight in these areas. 

Portfolio activity

We added one new stock to the Fund in October in the form of international home improvement retail group Kingfisher, owner of brands such as B&Q and Screwfix in the UK and Brico Depot and Castorama in France. Its shares are trading around a 7-8 year relative low, on a P/E of c. 12.5x and currently yield nearly 4% while the company has c. £600m net cash on its balance sheet. 

The recently appointed management team has articulated a strategy that if executed would add £500m to annual profits by the year ending January 2021 (using 2016 as the base year when the group made c. £700m). This is a potential material step change in profitability about which the stock market is highly sceptical despite early evidence of traction. The £500m is to be generated by optimising operational efficiency (which should be relatively low risk), improving digital capability (which was needed) and creating a unified and unique offer that is sold across the group. The latter is the most material part of the total estimated gains (70%) but will be the most difficult to execute. On the current valuation, the share price is assuming no success with this new strategy, which creates a useful risk/reward dynamic.

The new strategy is not the only attraction of Kingfisher. Firstly, it also offers exposure to the recovering French economy (something that is hard to find via UK-listed stocks), with c. 40% of EBIT sourced from France via its ownership of Castorama and Brico Depot. Secondly, Screwfix (c. 20% of group EBIT) has one of the best organic growth records in the whole market, if considered separately. Thirdly, Kingfisher owns c. £3.5bn of freehold property. Fourthly and finally, it has a strong position in the vibrant Polish market. 

The weakest part of the group, in our view, is B&Q, which accounts for c. 25% of EBIT. However, this business will also benefit from the new strategy and investment in digital and could be boosted by a retrenchment by Bunnings, the Australian retailer that acquired Homebase a few years ago. Recent results from this business suggest the Bunnings UK axis is struggling. 

In other activity, we continued to add to recent new additions Hammerson and Central Asia Metals. We also continued to reduce our positions in both AstraZeneca and Laird into strength. We have outlined the rationale for these changes in recent monthly reports. In the former, we are now down to a c. 50bp overweight, with the stock being 3% of the Fund. AstraZeneca is our only holding in the pharmaceuticals sector; we do not own any GlaxoSmithKline, which, as noted above, had weak results; it also presented a confused picture on its dividend outlook. We continue to think Glaxo has a number of challenges, including its level of debt, potential liabilities from various put options, competitive challenges in a number of its large businesses (e.g. its HIV franchise) and that its P&L (and hence EPS and P/E-based valuations) does not include a number of material cash items (e.g. certain royalties). AstraZeneca has some of these traits, which is why we are comfortable reducing the weighting given how the share price has recovered, and in running a large underweight in the sector.

We also reduced DS Smith slightly, which has been a good performer recently, and Sainsbury, where near term trends, based on industry data, appear sluggish. We added to ITV, which continues to underperform despite evidence that TV advertising is recovering. We also topped up our Vodafone position, which has continued to perform poorly (down c. 10% relative the past year). 

Outlook

The path to policy normalisation has categorically begun in the US, the UK and Europe. The true distortive impact of effectively zero interest rates in the developed world on various asset classes will only become apparent in future years. However, without doubt it has pushed valuations of many assets and individual instruments to elevated levels that will be hard to justify if the cost of capital rises. There are also a number of geopolitical risks that also make for a more cautious tone – namely Korea, Trump’s progress (or lack of) on policy, Trump / Russia, the tensions in the Middle East, Brexit, etc.

Within the equity markets, we strongly believe that the overvaluation is most apparent in consumer staples and other perceived defensive sectors such as utilities and pharmaceuticals. It is pleasing that we are starting to see chinks in the armour in the operational performances of these businesses. Conversely, we believe that many of the areas that we are exposed to will respond well to a change of stock market leadership if monetary policy were to normalise, particularly financials. Elsewhere, valuations in both the oil and mining sectors continue to look attractive to us, whilst there are also selective opportunities in the UK domestic arena, too. 

The long-term performance of the Fund is heavily correlated to the Fund’s dividend growth and the resulting absolute level of the dividend. As we discussed two months ago, the dividend growth of the Fund remains robust – our current guidance is between 9-11% in 2017. We will provide a final update on the 2017 dividend growth in early December, with the risk remaining to the upside. The Fund yields c. 4.15% based on this 2017 dividend stream. This starting yield, strong dividend growth (which we expect to continue in 2018), the low valuations embedded across the portfolio, coupled with the shift in monetary policy, leave us cautiously optimistic in our outlook for the Fund. 
 

Disclaimer

If you would like further information about the Fund, please call our Investor Relations team on +44 (0) 20 7747 8969, email us at info@johcm.co.uk or visit our website at www.johcm.com

This document is for professional investors only. Source: JOHCM/Bloomberg unless otherwise stated. Issued and approved in the UK by J O Hambro Capital Management Limited (the “Investment Manager”), which is authorised and regulated by the Financial Conduct Authority. JOHCM® is a registered trademark of J O Hambro Capital Management Ltd. J O Hambro® is a registered trademark of Barnham Broom Holdings Ltd. Registered address: Ground Floor, Ryder Court, 14 Ryder Street, London SW1Y 6QB. Registered in England and Wales under No: 2176004. Telephone calls may be recorded.

The information in this document does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for Funds described in this document; nor shall this document, or any part of it, or the fact of its distribution form the basis of, or be relied on, in connection with any contract. 

The information contained herein including any expression of opinion is for information purposes only and is given on the understanding that it is not a recommendation. Allocations and holdings are subject to change. 

Recipients of this document who intend to subscribe to any of the Funds are reminded that any such purchase may only be made solely on the basis of the information contained in the prospectus in its final form, which may be different from the information contained in this document.  No reliance may be placed for any purpose whatsoever on the information contained in this document or on the completeness, accuracy or fairness thereof. 

No representation or warranty, express or implied, is made or given by or on behalf of the Firm or its partners or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this document, and no responsibility or liability is accepted for any such information or opinions (but so that nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently).

The distribution of this document in certain jurisdictions may be restricted by law; therefore, persons into whose possession this document comes should inform themselves about and observe any such restrictions.  Any such distribution could result in a violation of the law of such jurisdictions.

The information contained in this presentation has been verified by the firm. It is possible that, from time to time, the Fund manager may choose to vary self imposed guidelines contained in this presentation in which case some statements may no longer remain valid. We recommend that prospective investors request confirmation of such changes prior to investment. Notwithstanding, all investment restrictions contained in specific Fund documentation such as prospectuses, supplements or placement memoranda or addenda thereto may be relied upon. 

Investments fluctuate in value and may fall as well as rise. Investors may not get back the value of their original investment. 

Past performance is not necessarily a guide to future performance. Dividend yield quoted is prospective and is not guaranteed.

Investors should note that there may be no recognised market for investments selected by the Investment Manager and it may, therefore, be difficult to deal in the investments or to obtain reliable information about their value or the extent of the risks to which they are exposed.

The Investment Manager may undertake investments on behalf of the Fund in countries other than the investors’ own domicile. Investors should also note that changes in rates of exchange may cause the value of investments to go up or down.

J O Hambro Capital Management Ltd is licensed by FTSE to redistribute the FTSE All-Share TR Index, the “Index”.  All rights in and to the Index and trade mark vest in FTSE and/or its licensors (including the Financial Times Limited and the London Stock Exchange PLC), none of whom shall be responsible for any error or omission in the Index.

For a better experience, we recommend viewing this website in landscape orientation.

Webinars

×

JOHCM

×

Regnan

×